

Single-Cell Mass Spectrometry Enables Insight into Heterogeneity in Infectious Disease

Tra D. Nguyen,[#] Yunpeng Lan,[#] Shelley S. Kane, Jacob J. Haffner, Renmeng Liu, Laura-Isobel McCall,^{*} and Zhibo Yang^{*}



Cite This: *Anal. Chem.* 2022, 94, 10567–10572



Read Online

ACCESS |




Metrics & More



Article Recommendations



Supporting Information



ABSTRACT: Cellular heterogeneity is generally overlooked in infectious diseases. In this study, we investigated host cell heterogeneity during infection with *Trypanosoma cruzi* (*T. cruzi*) parasites, causative agents of Chagas disease (CD). In chronic-stage CD, only a few host cells are infected with a large load of parasites and symptoms may appear at sites distal to parasite colonization. Furthermore, recent work has revealed *T. cruzi* heterogeneity with regard to replication rates and drug susceptibility. However, the role of cellular-level metabolic heterogeneity in these processes has yet to be assessed. To fill this knowledge gap, we developed a Single-probe SCMS (single-cell mass spectrometry) method compatible with biosafety protocols, to acquire metabolomics data from individual cells during *T. cruzi* infection. This study revealed heterogeneity in the metabolic response of the host cells to *T. cruzi* infection in vitro. Our results showed that parasite-infected cells possessed divergent metabolism compared to control cells. Strikingly, some uninfected cells adjacent to infected cells showed metabolic impacts as well. Specific metabolic changes include increases in glycerophospholipids with infection. These results provide novel insight into the pathogenesis of CD. Furthermore, they represent the first application of bioanalytical SCMS to the study of mammalian-infectious agents, with the potential for broad applications to study infectious diseases.

Cell heterogeneity is commonly present in nearly all biological systems. In addition to genetic variation, cellular heterogeneity can be induced by nongenetic mechanisms, i.e., cells possessing similar genotypes but actually expressing morphological and phenotypical differences.¹ Although cell heterogeneity has been reported in human diseases such as cancer, diabetes, and chronic and age-related diseases,² it is largely understudied in infectious disease. For the first time, this study will pave the way to study the heterogeneity that presents in infection with *Trypanosoma cruzi* (*T. cruzi*) at the single-cell level.


T. cruzi is a protozoan parasite causing Chagas disease (CD), which is an understudied tropical disease with severe cardiac and gastrointestinal symptoms. At the cellular level, *T. cruzi* trypomastigotes invade host cells and differentiate into amastigotes, which can proliferate, differentiate back into trypomastigotes, and then escape the host cells. These newly produced trypomastigotes can then invade new cells and

continue this cycle of damage.³ *T. cruzi* infection results in a major deregulation of lipid and glucose metabolism in the host cells.⁴ Metabolic alterations proportional to CD severity were observed in the heart during experimental *T. cruzi* infection.⁵ Differential spatial distribution of metabolic alterations in experimentally infected animals reflects sites of Chagas disease tropism.⁶ However, all of these reported studies have been performed using traditional metabolomic, gene expression, or functional studies from extracts and lysates prepared from cell

Received: May 27, 2022

Accepted: July 17, 2022

Published: July 21, 2022



populations or infected tissues, which masks cellular-level heterogeneity and cellular-level spatiality.

Although single-cell transcriptomics⁷ and proteomics⁸ are increasingly implemented, metabolomics at the single-cell level can investigate cellular function that may not be rendered by other methods. Metabolites are smaller molecules (<1.5 kDa), including sugars, lipids, and amino acids.⁹ Metabolites reflect cell status and unveil functions of associated metabolic pathways. Single-cell metabolomics has a great potential to uncover the phenotypic variations from cell to cell and, specifically, cellular heterogeneity. In metabolomic studies, mass spectrometry (MS) has become an important tool due to its high sensitivity, broad molecular coverage, and powerful structural identification capabilities. Traditional MS studies rely on bulk samples that do not reveal molecular information at the single-cell level and often mask cellular heterogeneity. In contrast, single-cell mass spectrometry (SCMS) is capable of profiling metabolites in individual cells and unveiling hidden subpopulations of cells. MS-based single-cell metabolomics is capable of analyzing and determining the cellular metabolites that are altered after environmental perturbation.¹⁰ A series of SCMS techniques have been developed to analyze cells under vacuum (e.g., MALDI-MS (matrix-assisted laser desorption/ionization-MS) and SIMS (secondary ion mass spectrometry))¹¹ or ambient environment (e.g., live single-cell video-MS,¹² probe ESI MS,¹³ LAESI MS,¹⁴ and nano-DESI MS¹⁵). We have developed multiple microscale sampling and ionization devices, including the Single-probe,¹⁶ micropipette¹⁷ and T-probe,¹⁸ that can be coupled to MS for single-cell metabolomics studies. Among them, the Single-probe SCMS method has been routinely used in our studies. Briefly, the Single-probe is a home-built device composed of a solvent-providing capillary, a dual-bore quartz needle, and a nano-ESI emitter. The Single-probe can be coupled to a mass spectrometer for microscale sampling (e.g., from single cells and tissue slices) and MS analysis (Figure 1a). The Single-probe tip is small enough ($\sim 9\ \mu\text{m}$) for insertion into single cells. The sampling solvent (50/50 acetonitrile/methanol (v/v)) with 0.1% formic acid) was continuously delivered to extract cellular contents, which are immediately ionized by MS analysis (Figure 1b).^{16,19} We have used this technique in different single-cell studies such as investigating the difference in drug resistance,^{19a,20} quantifying anticancer drugs in single cells,^{19c,21} comparing metabolites in cancer stem cells and nonstem cancer cells,²² and determining the influence of the environment on algal cell metabolites.²³ In addition, the Single-probe device has been utilized for MS imaging studies to acquire the spatial distribution of molecules on tissue slices^{19f,24} as well as to analyze secreted metabolites inside multicellular spheroids.²⁵

In the current study, we focused on metabolomics of single cells infected by *T. cruzi*, due to the crucial role of metabolism in CD.^{6c,26} The experiments were conducted using the Single-probe SCMS technique to analyze HeLa cells, which were used as the model system in three different groups: *T. cruzi*-infected, bystander (i.e., uninfected cells that are adjacent to infected cells), and control cells (no parasite exposure). Our results revealed striking bystander effects of infection, including metabolic pathways commonly perturbed in infected cells and bystander cells. These results help improve our understanding of host pathways of CD pathogenesis and may help develop new treatments to address late-stage disease that cannot be cured by antiparasitic agents. Furthermore, our




Figure 1. (a) Single-probe single-cell mass spectrometry (SCMS) setup. (b) Schematic of the working mechanisms of the experimental setup.

approach is compatible with biosafety protocols and thus should have broad applicability to other intracellular pathogenic agents.

During chronic *T. cruzi* infection, only a minority of cells are infected.²⁷ Although parasite persistence is required for disease progression,²⁸ CD symptoms can nevertheless develop even with low parasite load that may be spatially disconnected from sites of tissue damage.²⁹ SCMS analyses of infected and uninfected cells in the same culture plate, in comparison to control wells, can deconvolute direct effects of *T. cruzi* infection from bystander effects of infection. HeLa cells were used as a model and infected with β -galactosidase-expressing *T. cruzi*.³⁰ Cells were fixed by glutaraldehyde to kill the parasites and ensure biosafety. The fixed parasites were then stained with X-gal, enabling us to clearly differentiate parasite-containing cells (containing blue amastigote-stage parasites) from bystander cells (do not contain blue-staining regions) by bright-field microscopy (Figure 2a). These observations match with previous publications regarding this parasite strain.³¹ SCMS measurements were performed not only on these infected and bystander cells but also on control cells from a separate, uninfected culture well.

PCA (principal component analysis) showed that the fixation and staining processes had no significant influence on the overall cellular metabolite profiles (Figure 2b and Supporting Information Figure S4a). This conclusion was




Figure 2. Influence of the optimized fixation and staining processes on the overall profiles of cellular metabolites in HeLa cells infected by *T. cruzi*. (a) Bright-field microscopy picture of HeLa cells infected with β -galactosidase-expressing *T. cruzi*. Cells were fixed by glutaraldehyde and stained by X-gal. Individual *T. cruzi* parasites become stained a deep blue, so that infected cells with intracellular *T. cruzi* amastigotes (stained as deep blue in an oval shape; infected cells indicated by red asterisks) can be distinguished from bystander cells (adjacent uninfected cells; representative cell indicated by a black arrow) that remain clear. (b) PCA results. Without parasite infection, cells have comparable profiles of metabolites without (control) and with (stained) the fixation and staining processes. Cells exposed to parasites (infected and bystander cells) present significantly different metabolite profiles than unexposed cells (control and stained).

further confirmed by PLS-DA (partial least-squares discriminant analysis) ($p = 0.49$ by permutation test, Figure S4b,c). As expected, parasite-containing cells have different overall metabolite compositions compared to bystander cells. However, strikingly, both cell types differed in terms of overall metabolome from control and stained cells (both are uninfected). This finding supports bystander effects of *T. cruzi* infection on the overall cellular metabolome and provides a metabolic mechanism to explain the development of Chagas disease lesions at sites with low parasite burden.³²

PCA results showed that a subset of bystander cells was particularly similar to (i.e., overlapped with) infected cells from the same culture plate (Figure 2b and Figure 3a). Indeed, random forest machine learning algorithms misclassified 16 out of 53 bystander cells as infected (Table 1). In contrast, 62 out of 68 infected cells were correctly classified. It is worth noting that a large portion of control cells was misclassified as stained cells and vice versa, supporting that fixation and staining

Table 1. Random Forest Classification of Single Cells

	predicted				classification error
	control	stained	infected	bystander	
correct					
control	48	12	1	0	0.213
stained	25	13	0	0	0.658
infected	0	1	62	5	0.014
bystander	3	1	16	33	0.32

processes have no significant influence on cell metabolites. We then manually regrouped the bystander cells into correctly classified and misclassified subgroups and conducted PCA. We observed a high degree of similarity between the misclassified and infected cells (Figure 3b). To determine metabolites with significantly different abundances among the infected cells and the two bystander groups (correctly classified and misclassified infected cells), we performed ANOVA (with false discovery rate (FDR) correction and adjusted p -value ≤ 0.05) (Table S4 and Figure S1). We obtained 16 ions from all groups possessing strikingly similar patterns for both misclassified bystander cells and infected cells across two independent experimental replicates (e.g., lower levels of m/z 267.0620, 322.886, and 359.025 compared to correctly classified bystander cells) (Table S4 and Figure S2).

To annotate these ions, we performed MS/MS of both single cells (using the Single-probe SCMS method) and cell lysate (using LC-MS/MS). Similar to our previous studies,^{19a,33} some species could only be detected in the SCMS experiments, likely due to multiple reasons (e.g., differences in sample preparation methods, matrix compositions, and stabilities of molecules during sample preparation) (Table S4). As expected in untargeted metabolomics,³⁴ most metabolite features could not be annotated (Table S4). Among all annotatable metabolites, m/z 756.547 was annotated as PC(34:3), LPC(34:4), or PC(O-34:4) (Table S4 and Figure 4). This lipid significantly differed in abundance between cell groups ($p = 2.33 \times 10^{-4}$ using ANOVA test with false discovery rate correction (Figure 4a)). It is interesting to note that, similar to infected cells, misclassified bystander cells also contain higher abundances of this species (Figure 4a). Other infection-elevated metabolites were also annotated as glycerophosphocholines (GPCs), including m/z 768.583,




Figure 3. Impact of *T. cruzi* infection on the metabolome of bystander uninfected cells. (a) PCA of SCMS data highlighting metabolic overlap between *T. cruzi* infected cells and a subset of bystander cells. (b) PCA analysis of SCMS data as in panel a, colored based on random forest classifier prediction. Misclassified uninfected bystander cells have overall metabolomes similar to infected cells.




Figure 4. Representative glycerophosphocholine (m/z 756.547) differentiating between cell groups. (a) Normalized intensity of PC(34:3) in three different cell types ($p = 0.000233$ using ANOVA test with FDR correction). (b) LC-MS/MS mirror plot supporting PC annotation. Green, reference library MS/MS spectrum for 1-oleoyl-2-palmitoyl-*sn*-glycero-3-phosphocholine (PC 34:1). Black, experimental MS/MS spectrum for m/z 756.547. m/z 756.547 is smaller by 4.03 than that of 1-oleoyl-2-palmitoyl-*sn*-glycero-3-phosphocholine.

780.5460, 782.5630, 808.5770, and 810.5940 (Table S4 and Figure S3). This observation concurs with our prior findings of infection-elevated GPCs in heart tissue in proportion to disease severity and in the infected esophagus and large intestine, in mice across multiple infection time points and parasite strains.^{4b,5a,6a,b} While confidently assigning a parasite vs host origin to these GPCs is challenging, very long-chain GPCs and lysoglycerophosphocholines (Lyso-GPCs) are elevated in isolated amastigote-stage *T. cruzi* compared to host cells.³⁵ These findings may support further redevelopment of therapeutics targeting phosphatidylcholine metabolism, such as miltefosine, currently in clinical use for the related parasite *Leishmania*, but in this case to target the metabolic consequences of infection on the host.³⁶

In conclusion, we used the Single-probe SCMS technique for metabolomics studies of cells with heterogeneous infection by *T. cruzi* at the single-cell level. This represents, to the best of our knowledge, the first implementation of single-cell metabolomics in mammalian-infectious disease. We discovered that necessary cell fixation (to kill the parasites) and staining (to illustrate *T. cruzi* infection) have no significant influence on the overall cell metabolome (Figures 2b and S4). Our results demonstrate for the first time bystander effects of *T. cruzi* on infection-adjacent uninfected cells (Figures 2b, 3, and 4). Although our current studies cannot fully explain the mechanism of this bystander effect, uneven infection may be due to pre-existing heterogeneity of host cells. For example, the bystander cells may belong to a subpopulation of host cells containing lower levels of nutrients needed to support parasite

intracellular replication. Alternatively, these differences may be established subsequent to parasite infection, through the secretion of metabolites or proteins by infected cells that reshape bystander cell metabolism.

Our results provide a significant insight into CD pathogenesis, explaining lesion development in sites that do not contain parasites.²⁹ This has major implications for CD treatment, indicating that killing parasites alone may not be sufficient. Our results may explain the failure of the benznidazole evaluation for interrupting trypanosomiasis (BENEFIT) clinical trial³⁷ and pave the way for future work to assess the role of metabolic heterogeneity in CD pathogenesis, tissue resilience, parasite dormancy, and antiparasitic susceptibility.

SAFETY CONSIDERATIONS

Silica capillaries pose a needle-stick hazard, and they must be handled with caution. Standard safety protocols are needed for the handling of chemicals and culturing and treating of cell lines. *T. cruzi* is classified at biosafety level 2 (BSL-2) in the United States. All unfixed *T. cruzi* should only be handled inside a biosafety cabinet by trained operators wearing safety glasses, laboratory coats and double gloves. Ambient experimentation on open parasite-containing receptacles outside of the biosafety cabinet should only be performed after fixation processes have killed the parasites.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.analchem.2c02279>.

Experimental details of cell culture, parasite culture, cell infection and staining, Single-probe single-cell mass spectrometry, and LC-MS/MS and GNPS parameters; tables of annotated metabolites and their MS/MS spectra; boxplot and hierarchical clustering of metabolites; PCA and PLS-DA analyses; Python script and R script (PDF)

AUTHOR INFORMATION

Corresponding Authors

Zhibo Yang – Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States; orcid.org/0000-0003-0370-7450; Email: Zhibo.Yang@ou.edu

Laura-Isobel McCall – Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States; Laboratories of Molecular Anthropology and Microbiome Research and Department of Microbiology and Plant Biology, University of Oklahoma, Norman, Oklahoma 73019, United States; Email: LMccall@ou.edu

Authors

Tra D. Nguyen – Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States

Yunpeng Lan – Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States

Shelley S. Kane – Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States

Jacob J. Haffner – Laboratories of Molecular Anthropology and Microbiome Research and Department of Anthropology, University of Oklahoma, Norman, Oklahoma 73019, United States

Renmeng Liu – Department of Chemistry and Biochemistry, University of Oklahoma, Norman, Oklahoma 73019, United States; Present Address: (R.L.) Drug Metabolism, Gilead Sciences Inc., Foster City, CA, 94404, USA. Email: renmeng.liu4@gilead.com

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.analchem.2c02279>

Author Contributions

[#]T.D.N. and Y.L. contributed equally to this work.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by start-up funds from the University of Oklahoma (to L.-I.M.). L.-I.M. holds an Investigators in the Pathogenesis of Infectious Disease Award from the Burroughs Wellcome Fund. Z.Y. is supported by the National Institutes of Health (Grant R01GM116116), National Science Foundation (Grant OCE-1634630), and Research Council of the University of Oklahoma Norman Campus. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

REFERENCES

- (1) (a) Xin, X.; Wang, H.; Han, L.; Wang, M.; Fang, H.; Hao, Y.; Li, J.; Zhang, H.; Zheng, C.; Shen, C. *J. Virol.* **2018**, *92* (9), e00179–18. (b) Raj, A.; Rifkin, S. A.; Andersen, E.; van Oudenaarden, A. *Nature* **2010**, *463* (7283), 913–8.
- (2) Kamies, R.; Martinez-Jimenez, C. P. *Mamm. Genome* **2020**, *31* (5), 170–180.
- (3) Fernandes, M. C.; Andrews, N. W. *FEMS Microbiol. Rev.* **2012**, *36* (3), 734–47.
- (4) (a) D'Avila, H.; Freire-de-Lima, C. G.; Roque, N. R.; Teixeira, L.; Barja-Fidalgo, C.; Silva, A. R.; Melo, R. C.; Dosreis, G. A.; Castro-Faria-Neto, H. C.; Bozza, P. T. *J. Infect. Dis.* **2011**, *204* (6), 951–61. (b) Nagajyothi, F.; Desruisseaux, M. S.; Weiss, L. M.; Chua, S.; Albanese, C.; Machado, F. S.; Esper, L.; Lisanti, M. P.; Teixeira, M. M.; Scherer, P. E.; Tanowitz, H. B. *Memórias do Instituto Oswaldo Cruz* **2009**, *104*, 219–225.
- (5) (a) Hoffman, K.; Liu, Z.; Hossain, E.; Bottazzi, M. E.; Hotez, P. J.; Jones, K. M.; McCall, L. I. *ACS Infect. Dis.* **2021**, *7* (6), 1638–1649. (b) McCall, L. I.; Morton, J. T.; Bernatchez, J. A.; de Siqueira-Neto, J. L.; Knight, R.; Dorrestein, P. C.; McKerrrow, J. H. *Anal. Chem.* **2017**, *89* (19), 10414–10421.
- (6) (a) Dean, D. A.; Gautham, G.; Siqueira-Neto, J. L.; McKerrrow, J. H.; Dorrestein, P. C.; McCall, L. I. *PLOS Neglected Tropical Diseases* **2021**, *15* (10), No. e0009819. (b) Hossain, E.; Khanam, S.; Dean, D. A.; Wu, C.; Lostracco-Johnson, S.; Thomas, D.; Kane, S. S.; Parab, A. R.; Flores, K.; Katemauswa, M.; Gosmanov, C.; Hayes, S. E.; Zhang, Y.; Li, D.; Woelfel-Monsivais, C.; Sankaranarayanan, K.; McCall, L. I. *Sci. Adv.* **2020**, *6* (30), No. eaaz2015. (c) Liu, Z.; Ulrich vonBargen, R.; McCall, L. I. *Curr. Opin. Microbiol.* **2021**, *63*, 204–209.
- (7) (a) Kolodziejczyk, A. A.; Kim, J. K.; Svensson, V.; Marionni, J. C.; Teichmann, S. A. *Mol. Cell* **2015**, *58* (4), 610–620. (b) Bengtsson, M.; Hemberg, M.; Rorsman, P.; Ståhlberg, A. *BMC Molecular Biology* **2008**, *9* (1), 63. (c) Drayman, N.; Patel, P.; Vistain, L.; Tay, S. *eLife* **2019**, *8*, No. e46339.
- (8) (a) Albayrak, C.; Jordi, C. A.; Zechner, C.; Lin, J.; Bichsel, C. A.; Khamash, M.; Tay, S. *Mol. Cell* **2016**, *61* (6), 914–24. (b) Zhang, Y.; Naguro, I.; Herr, A. E. *Angew. Chem., Int. Ed.* **2019**, *58* (39), 13929–13934.
- (9) (a) Minakshi, P.; Ghosh, M.; Kumar, R.; Patki, H. S.; Saini, H. M.; Ranjan, K.; Brar, B.; Prasad, G. Single-Cell Metabolomics: Technology and Applications. In *Single-Cell Omics*; Barh, D.; Azevedo, V., Eds.; Academic Press: 2019; Chapter 15, pp 319–353. DOI: 10.1016/B978-0-12-814919-5.00015-4. (b) Kumar, R.; Ghosh, M.; Kumar, S.; Prasad, M. *Front. Microbiol.* **2020**, *11*, 1152.
- (10) Dolatmoradi, M.; Samarah, L. Z.; Vertes, A. *Anal. Sens.* **2022**, *2* (1), No. e202100032.
- (11) (a) Boggio, K. J.; Obasuyi, E.; Sugino, K.; Nelson, S. B.; Agar, N. Y. R.; Agar, J. N. *Expert Rev. Proteomic* **2011**, *8* (5), 591–604. (b) Jungnickel, H.; Laux, P.; Luch, A. *Toxics* **2016**, *4* (1), 5.
- (12) Masujima, T. *Anal. Sci.* **2009**, *25* (8), 953–960.
- (13) Gong, X. Y.; Zhao, Y. Y.; Cai, S. Q.; Fu, S. J.; Yang, C. D.; Zhang, S. C.; Zhang, X. R. *Anal. Chem.* **2014**, *86* (8), 3809–3816.
- (14) Shrestha, B.; Vertes, A. *Anal. Chem.* **2009**, *81* (20), 8265–8271.
- (15) Bergman, H. M.; Lanekoff, I. *Analyst* **2017**, *142* (19), 3639–3647.
- (16) Pan, N.; Rao, W.; Kothapalli, N. R.; Liu, R.; Burgett, A. W. G.; Yang, Z. *Anal. Chem.* **2014**, *86* (19), 9376–9380.
- (17) Zhu, Y.; Wang, W.; Yang, Z. *Anal. Chem.* **2020**, *92* (16), 11380–11387.
- (18) Liu, R.; Pan, N.; Zhu, Y.; Yang, Z. *Anal. Chem.* **2018**, *90* (18), 11078–11085.
- (19) (a) Liu, R.; Sun, M.; Zhang, G.; Lan, Y.; Yang, Z. *Anal. Chim. Acta* **2019**, *1092*, 42–48. (b) Standke, S. J.; Colby, D. H.; Bensen, R. C.; Burgett, A. W. G.; Yang, Z. *Anal. Chem.* **2019**, *91* (3), 1738–1742. (c) Pan, N.; Standke, S. J.; Kothapalli, N. R.; Sun, M.; Bensen, R. C.; Burgett, A. W. G.; Yang, Z. *Analytical chemistry* **2019**, *91* (14), 9018–9024. (d) Sun, M.; Tian, X.; Yang, Z. *Anal. Chem.* **2017**, *89* (17), 9069–9076. (e) Standke, S. J.; Colby, D. H.; Bensen, R. C.; Burgett, A. W. G.; Yang, Z. *J. Vis. Exp.* **2019**, *148*, e59875. (f) Tian, X.; Zhang, G.; Zou, Z.; Yang, Z. *Anal. Chem.* **2019**, *91* (9), 5802–5809.
- (20) Liu, R.; Zhang, G.; Yang, Z. *Chem. Commun. (Camb)* **2019**, *55* (5), 616–619.
- (21) (a) Roberts, B. L.; Severance, Z. C.; Bensen, R. C.; Le, A. T.; Kothapalli, N. R.; Nuñez, J. I.; Ma, H.; Wu, S.; Standke, S. J.; Yang, Z.; Reddig, W. J.; Blewett, E. L.; Burgett, A. W. G. *ACS Chem. Biol.* **2019**, *14* (2), 276–287. (b) Liu, M.; Zhang, Y.; Yang, J.; Cui, X.; Zhou, Z.; Zhan, H.; Ding, K.; Tian, X.; Yang, Z.; Fung, K. A.; Edil, B. H.; Postier, R. G.; Bronze, M. S.; Fernandez-Zapico, M. E.; Stemmler, M. P.; Brabletz, T.; Li, Y. P.; Houchen, C. W.; Li, M. *Gastroenterology* **2020**, *158* (3), 679–692 e1. (c) Bensen, R. C.; Standke, S. J.; Colby, D. H.; Kothapalli, N. R.; Le-McClain, A. T.; Patten, M. A.; Tripathi, A.; Heinlen, J. E.; Yang, Z.; Burgett, A. W. G. *ACS Pharmacology & Translational Science* **2021**, *4* (1), 96–100.
- (22) Sun, M.; Yang, Z. *Anal. Chem.* **2019**, *91* (3), 2384–2391.
- (23) Sun, M.; Yang, Z.; Wawrik, B. *Front. Plant Sci.* **2018**, *9*, 571.
- (24) (a) Rao, W.; Pan, N.; Yang, Z. *J. Am. Soc. Mass Spectrom.* **2015**, *26* (6), 986–993. (b) Rao, W.; Pan, N.; Tian, X.; Yang, Z. *J. Am. Soc. Mass Spectrom.* **2016**, *27* (1), 124–134. (c) Rao, W.; Pan, N.; Yang, Z. *J. Vis. Exp.* **2016**, *112*, e53911. (d) Tian, X.; Xie, B.; Zou, Z.; Jiao, Y.; Lin, L.-E.; Chen, C.-L.; Hsu, C.-C.; Peng, J.; Yang, Z. *Anal. Chem.* **2019**, *91* (20), 12882–12889.
- (25) Sun, M.; Tian, X.; Yang, Z. *Anal. Chem.* **2017**, *89* (17), 9069–9076.
- (26) Dumoulin, P. C.; Burleigh, B. A. *Curr. Opin. Microbiol.* **2021**, *63*, 244–249.
- (27) (a) Khan, A. A.; Langston, H. C.; Costa, F. C.; Olmo, F.; Taylor, M. C.; McCann, C. J.; Kelly, J. M.; Lewis, M. D. *PLOS Pathogens* **2021**, *17* (8), No. e1009864. (b) Ward, A. I.; Lewis, M. D.; Khan, A. A.; McCann, C. J.; Francisco, A. F.; Jayawardhana, S.; Taylor, M. C.; Kelly, J. M. *mBio* **2020**, *11* (4), No. e01242-20.
- (28) Tarleton, R. L. *Trends Parasitol.* **2003**, *19* (10), 447–51.
- (29) (a) Marcon, G. E.; de Albuquerque, D. M.; Batista, A. M.; Andrade, P. D.; Almeida, E. A.; Guariento, M. E.; Teixeira, M. A.

- Costa, S. C. *Mem. Inst. Oswaldo Cruz* **2011**, *106* (1), 85–91.
- (b) Ward, A. I.; Lewis, M. D.; Taylor, M. C.; Kelly, J. M. *bioRxiv* **2022**, 90, e0038221.
- (30) Buckner, F. S.; Verlinde, C. L.; La Flamme, A. C.; Van Voorhis, W. C. *Antimicrob. Agents Chemother.* **1996**, *40* (11), 2592–7.
- (31) (a) Buckner, F. S.; Verlinde, C. L.; LaFlamme, A. C.; Van Voorhis, W. C. *Antimicrob. Agents Chemother.* **1996**, *40* (11), 2592–2597. (b) Buckner, F. S.; Wilson, A. J.; Van Voorhis, W. C. *Infect. Immun.* **1999**, *67* (1), 403–9.
- (32) Higuchi, M. d. L.; De Brito, T.; Martins Reis, M.; Barbosa, A.; Bellotti, G.; Pereira-Barreto, A. C.; Pileggi, F. *Cardiovasc Pathol* **1993**, *2* (2), 101–106.
- (33) Liu, R.; Yang, Z. *Anal. Chim. Acta* **2021**, *1143*, 124–134.
- (34) da Silva, R. R.; Dorrestein, P. C.; Quinn, R. A. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112* (41), 12549–12550.
- (35) Gazos-Lopes, F.; Martin, J. L.; Dumoulin, P. C.; Burleigh, B. A. *PLOS Pathogens* **2017**, *13* (12), No. e1006800.
- (36) (a) Vakil, N. H.; Fujinami, N.; Shah, P. J. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* **2015**, *35* (5), 536–545. (b) Sales Junior, P. A.; Molina, I.; Fonseca Murta, S. M.; Sánchez-Montalvá, A.; Salvador, F.; Corrêa-Oliveira, R.; Carneiro, C. M. *Am. J. Trop. Med. Hyg* **2017**, *97* (5), 1289–1303.
- (37) Morillo, C. A.; Marin-Neto, J. A.; Avezum, A.; Sosa-Estani, S.; Rassi, A.; Rosas, F.; Villena, E.; Quiroz, R.; Bonilla, R.; Britto, C.; Guhl, F.; Velazquez, E.; Bonilla, L.; Meeks, B.; Rao-Melacini, P.; Pogue, J.; Mattos, A.; Lazdins, J.; Rassi, A.; Connolly, S. J.; Yusuf, S. *N Engl J. Med.* **2015**, *373* (14), 1295–1306.